[CAS NO. 2127109-84-4] Ropsacitinib (PF-06826647)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [2127109-84-4]
Store
Catalog
SLK-S9676
Brand
Selleck
CAS
2127109-84-4
DESCRIPTION [2127109-84-4]
Overview
| MDL | MFCD32197240 |
|---|---|
| Molecular Weight | 383.41 |
| Molecular Formula | C20H17N9 |
| SMILES | N#CC[C@@]1(N2N=CC(C3=NC(C4=CN(C)N=C4)=CN5C3=CC=N5)=C2)C[C@H](C#N)C1 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6082 mL | 13.0409 mL | 26.0817 mL |
| 5 mM | 0.5216 mL | 2.6082 mL | 5.2163 mL |
| 10 mM | 0.2608 mL | 1.3041 mL | 2.6082 mL |
| 50 mM | 0.0522 mL | 0.2608 mL | 0.5216 mL |
Description
Ropsacitinib (PF-06826647, Tyk2-IN-8, compound 10) is a selective and orally administered inhibitor of with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. PF-06826647 (Tyk2-IN-8, compound 10) also inhibits and with IC50 of 383 nM and 74 nM, respectively. PF-06826647 (Tyk2-IN-8, compound 10) is used in the treatment of psoriasis (PSO).
In vitro
Ropsacitinib (PF-06826647, Tyk2-IN-8, compound 22) is a selective and orally administered inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. It also inhibits JAK1 and JAK2 with IC50 of 383 nM and 74 nM, respectively.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.